Met-RANTES

Drug Profile

Met-RANTES

Alternative Names: Methionylated RANTES; MetRANTES

Latest Information Update: 12 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Geneva Biomedical Research Institute; Merck Serono
  • Class Antiasthmatics; Antirheumatics; Chemokines
  • Mechanism of Action CCR1 receptor antagonists; CCR5 receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 28 Oct 2004 Data presented at the 68th Annual Scientific Meeting of the American College of Rheumatology and the 39th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2004) have been added to the Rheumatic Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top